U.S. Cancels Contract With Moderna to Develop Bird Flu Vaccine

Health Secretary Robert F. Kennedy Jr. has repeatedly questioned the safety of mRNA technology, which is used in the company’s shot.The Trump administration has delivered its latest blow to vaccines, canceling a nearly $600-million contract to the drugmaker Moderna that was intended to develop a shot for humans against bird flu.The decision also forfeited the U.S. government’s right to purchase doses ahead of a pandemic, and canceled an agreement set up by the Biden administration in January to prepare the nation for a potential bird flu pandemic. The Moderna contract built on a previous government investment of $175 million last year.The move was not entirely unexpected. The Department of Health and Human Services said earlier this year that it was reviewing the contract. And Health Secretary Robert F. Kennedy Jr. has repeatedly questioned the safety of mRNA technology, which is used in Moderna’s Covid vaccine.First used for the Covid vaccines made by Pfizer-BioNTech and Moderna, mRNA shots instruct the body to produce a fragment of the virus, which then sets off the body’s immune response.Andrew Nixon, a Health and Human Services spokesman, said: “After a rigorous review, we concluded that continued investment in Moderna’s H5N1 mRNA vaccine was not scientifically or ethically justifiable.”For several years, a type of avian flu known as H5N1 has circulated around the world, killing wild birds and domestic flocks, and spreading to a range of other species including bears and sea mammals.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe.

Read more →

Dinosaurs could hold key to cancer discoveries

New techniques used to analyze soft tissue in dinosaur fossils may hold the key to new cancer discoveries. Researchers have analyzed dinosaur fossils using advanced paleoproteomic techniques, a method that holds promise for uncovering molecular data from ancient specimens.

Read more →

Machine learning algorithm brings long-read sequencing to the clinic

SAVANA uses a machine learning algorithm to identify cancer-specific structural variations and copy number aberrations in long-read DNA sequencing data. The complex structure of cancer genomes means that standard analysis tools give false-positive results, leading to erroneous clinical interpretations of tumour biology. SAVANA significantly reduces such errors. SAVANA offers rapid and reliable genomic analysis to better analyse clinical samples, thereby informing cancer diagnosis and therapeutic interventions.

Read more →

Unlocking precise composition analysis of nanomedicines

Current regulations for nanomedicines overlook the effects of the different forms of the same element, such as ions, nanoparticles, and aggregates. In a recent study, researchers developed a new analytical method combining an asymmetric flow field-flow fractionation system and mass spectrometry to separately quantify these forms. This technique allows for better quality control and safety evaluation of metal-based nanomedicines, promoting their development and clinical use, with applications also extending to food, cosmetics, and the environment.

Read more →